company_name,company_overview,contact_name,contact_role,contact_linkedin,contact_email,subject,body,generated_at
MacroGenics,"MacroGenics is a biotechnology company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The company, based in Rockville, Maryland, USA, has a diverse pipeline of product candidates in various stages of development.",Scott Koenig,President and CEO at MacroGenics Inc,https://www.linkedin.com/in/scott-koenig-9721989,,Reviving Promising Assets: A Path Forward?,"Hi Scott, I've been following MacroGenics' journey, especially the resilience shown in reviving the diabetes drug initially discontinued by Lilly. It's a testament to your team's commitment to innovative solutions. At Convexia Bio, we specialize in leveraging AI to rescue and optimize drug assets, focusing on dose optimization, patient stratification, and more. Given your success in navigating similar challenges, I believe there's a unique opportunity for us to explore potential synergies. Could we set aside some time to discuss if any of your current or shelved projects might benefit from our AI-powered models? Best, Ayaan",2025-11-17 23:06:47.142492
MacroGenics,"MacroGenics is a biotechnology company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The company, based in Rockville, Maryland, USA, has a diverse pipeline of product candidates in various stages of development.",Stephen Eck,"MacroGenics, Inc.",https://www.linkedin.com/in/stephen-eck-694a2611,,Reviving Promising Assets: A New Chapter for MacroGenics?,"Hi Stephen, I've been following MacroGenics' journey, especially the resilience shown in reviving the diabetes drug initially discontinued by Lilly. It's a testament to the potential hidden in challenging assets. At Convexia Bio, we specialize in rescuing such drug assets using AI-powered models, focusing on dose optimization, patient stratification, and more. Given your company's innovative approach in oncology and beyond, I believe there's a unique opportunity for us to explore. Could we discuss any assets that might benefit from a fresh perspective? Warm regards, Ayaan, Co-founder at Convexia Bio",2025-11-17 23:06:54.197835
MacroGenics,"MacroGenics is a biotechnology company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The company, based in Rockville, Maryland, USA, has a diverse pipeline of product candidates in various stages of development.",Frank Perabo,"Vice President, Clinical Development",https://www.linkedin.com/in/frank-perabo-1a46a9212,,Reviving Potential: A New Life for Abandoned Assets?,"Hi Frank, I've been following MacroGenics' journey, especially the resilience shown in reviving the diabetes drug initially discontinued by Lilly. It's a testament to the depth of your scientific insights and commitment to impactful therapeutics. At Convexia Bio, we specialize in leveraging AI to breathe new life into assets like these, focusing on dose optimization, patient stratification, and more, to uncover hidden value. Given your track record and our expertise, I'm curious if there's an opportunity to explore how we might help reevaluate any assets you're passionate about but have faced challenges with. Would you be open to a brief chat about this? Best, Ayaan",2025-11-17 23:07:00.564317
MacroGenics,"MacroGenics is a biotechnology company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The company, based in Rockville, Maryland, USA, has a diverse pipeline of product candidates in various stages of development.",Ezio Bonvini,"MacroGenics, Inc.",https://www.linkedin.com/in/ezio-bonvini-6694b766,,Reviving Potential: A New Life for Unmet Assets?,"Hi Ezio, I've been following MacroGenics' journey, especially the resilience shown in the diabetes drug venture with Lilly. It's a testament to the depth of scientific insight within your team. At Convexia Bio, we harness AI to breathe new life into promising drug assets that faced hurdles, focusing on dose optimization, patient stratification, and more. Given your track record of not letting valuable science go unnoticed, I wonder if there's an opportunity for us to explore potential synergies. Could we discuss any assets that might benefit from a fresh AI-powered perspective? Warm regards, Ayaan Co-founder, Convexia Bio",2025-11-17 23:07:08.004721
MacroGenics,"MacroGenics is a biotechnology company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The company, based in Rockville, Maryland, USA, has a diverse pipeline of product candidates in various stages of development.",William Heiden,Healthcare executive & board chair/member,https://www.linkedin.com/in/wheiden,,Reviving Potential: A New Life for Unfulfilled Drug Assets?,"Dear William, I've been following MacroGenics' journey, particularly the resilience shown in reviving the diabetes drug initially discontinued by Lilly. It's a testament to the vision and scientific rigor at MacroGenics, especially in oncology, autoimmune disorders, and infectious diseases. At Convexia Bio, we specialize in leveraging AI to rescue promising drug assets, focusing on dose optimization, patient stratification, and combination therapy design. Given your experience with navigating the complex path of drug development and revival, I believe there's a unique opportunity for us to explore. Could we discuss any assets in your pipeline that might benefit from a fresh perspective? Warm regards, Ayaan Co-founder, Convexia Bio",2025-11-17 23:07:12.511337
